Meet Avance Clinical at BIO‑Europe 2025 in Vienna, Austria

The Australian Advantage for Early Phase Success

Avance Clinical specialises in helping European biotechs unlock the benefits of conducting early-phase clinical trials in Australia, including:

• Fast ethics approval & rapid start-up – be ready to dose in just 5–6 weeks.
• No IND requirement – skip the US regulatory overhead while still generating globally accepted data.
• Significant cost savings – access the up to 43.5% R&D tax rebate on eligible clinical spend.
• World-class sites & diverse patient populations – proven for quality and recruitment speed.
• Regulatory-ready data – accepted by TGA, FDA, EMA, MHRA, and more.

These advantages mean faster proof-of-concept, reduced costs, and a smoother path to later-phase trials in North America and Europe.

ClinicReady + GlobalReady: A Seamless Path from Australia to the World

Our ClinicReady program gets your early-phase trial underway quickly and cost-effectively in Australia. Then, our GlobalReady model takes you through to later phases in North America with a single, experienced CRO team—ensuring consistent quality, regulatory compliance, and speed at every step.